Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
“George is one of the most accomplished executives in the biotechnology industry, and we are honored to have him join our Board of Directors,” said
“Neurology remains one of the great areas of unmet need in medicine, and as we begin to see a new era of scientific breakthroughs in this field, I believe Voyager’s gene therapy and neuro-genetic medicine programs will represent significant advancement,” said Scangos. “As I have gotten to know the Voyager team, I have been impressed by the quality of the science and the team, and I look forward to advising them in their quest to enable disease-modifying and possibly curative neurotherapeutics.”
Scangos most recently served as President and CEO of Vir from 2016 to 2023. Under his leadership, the company successfully delivered life-saving therapies for Ebola and COVID-19 to millions of patients while also building a pipeline spanning five therapeutic areas. Prior to joining Vir, Scangos served as CEO and as a member of the Board of Biogen, Inc. for six years. Previously, he spent 14 years as President and CEO of Exelixis, Inc. Scangos has received numerous accolades and recognitions for his industry leadership. Notably, he was among the top 10 CEOs to be named as “Businessperson of the Year” by Fortune in 2014 and 2015. He was also named one of “The Best Performing CEOs in the World” by
Scangos’ appointment to Voyager’s Board of Directors became effective today.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Friedreich’s Ataxia, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “target,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.
For example, all statements made by Voyager regarding the contributions
All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the ability of
These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the
Source: Voyager Therapeutics, Inc.